Yabao Pharmaceutical Company, Inc., a leading pharmaceutical company in China, announced an exclusive license with privately held Primary Peptides, Inc., to develop and commercialise innovative products targeting PTEN nuclear translocation for the treatment of stroke.

Under the terms of the agreement, Yabao receives exclusive rights to develop and commercialise in China, Taiwan and Hong Kong while Primary Peptides retains rights in all other markets. Financial terms were not disclosed. “Yabao is pleased to be collaborating with Primary Peptides, a world leader in development of new peptide therapeutics in the cardiovascular and neuroscience areas,” commented Dr. Peng Wang, president R&D, Yabao Pharmaceutical Company.

“This opportunity for Yabao to expand on leading research to develop innovative products is further evidence of Yabao’s growing commitment to partner the best science to treat serious diseases in China.”

Dr. Max Cynader at Primary Peptides said “We are pleased to combine our expertise in early innovative drug discovery with the significant resources that Yabao Pharmaceutical Company can bring to developing groundbreaking new medicines. Brain protection following stroke represents a large unmet medical need, and this new peptide therapeutic has the potential to improve the lives of many stroke victims.”